These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2189281)

  • 1. The selectivity of a new progestin.
    Phillips A
    Acta Obstet Gynecol Scand Suppl; 1990; 152():21-4. PubMed ID: 2189281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
    Phillips A; Hahn DW; McGuire JL
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins.
    Phillips A; Demarest K; Hahn DW; Wong F; McGuire JL
    Contraception; 1990 Apr; 41(4):399-410. PubMed ID: 2335104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
    Anderson FD
    Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of the new progestogens in combination oral contraceptives.
    Rebar RW; Zeserson K
    Contraception; 1991 Jul; 44(1):1-10. PubMed ID: 1832625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
    Chez RA
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New knowledge in the physiology of hormonal contraceptives.
    Lobo RA; Stanczyk FZ
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nestorone: a progestin with a unique pharmacological profile.
    Kumar N; Koide SS; Tsong Y; Sundaram K
    Steroids; 2000; 65(10-11):629-36. PubMed ID: 11108869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
    Corson SL
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
    Janaud A; Rouffy J; Upmalis D; Dain MP
    Acta Obstet Gynecol Scand Suppl; 1992; 156():33-8. PubMed ID: 1324555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex hormone receptor binding, progestin selectivity, and the new oral contraceptives.
    Collins DC
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1508-13. PubMed ID: 8178899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin.
    Phillips A; Hahn DW; McGuire JL
    Steroids; 1990 Aug; 55(8):373-5. PubMed ID: 2122551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selectivity information on desogestrel.
    Collins D
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1010-6. PubMed ID: 8447353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays.
    Fuhrmann U; Slater EP; Fritzemeier KH
    Contraception; 1995 Jan; 51(1):45-52. PubMed ID: 7750284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives.
    Kloosterboer HJ; Vonk-Noordegraaf CA; Turpijn EW
    Contraception; 1988 Sep; 38(3):325-32. PubMed ID: 3139361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacology of newer progestogens.
    Kuhl H
    Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro.
    Wild MJ; Rudland PS; Back DJ
    J Steroid Biochem Mol Biol; 1993 May; 45(5):407-20. PubMed ID: 8499348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.